AmInvest Research Reports

Top Glove Corp - No demand lift from China despite Covid outbreak

Publish date: Mon, 16 Jan 2023, 11:29 AM
0 7,260
An official blog in I3investor to publish research reports provided by AmInvest research team.

All materials published here are prepared by AmInvest. For latest offers on AmInvest trading products and news, please refer to:

Tel: +603 2036 1800 / +603 2032 2888
Fax: +603 2031 5210

Office Hours
Monday to Thursday: 8:45am – 5:45pm
Friday: 8:45am – 5:00pm
(GMT +08:00 Malaysia)

Investment Highlights

  • We maintain our SELL call on Top Glove Corporation (Top Glove) with an unchanged fair value (FV) of RM0.60/share. This is pegged to a target FY24F PE of 20x, at parity to its 10-year average. There is no ESG-related FV adjustment based on our unchanged 3-star rating.
  • Following a recent meeting with management, we increased FY23F loss by 2.6x to RM349.6mil due to lower plant utilisation (PU) assumptions given the lower-than-expected PU in Dec 2022 and Jan 2023. However, we maintain FY24F-25F earnings on expectations that demand could improve by the middle of 2023.
  • These are the salient highlights from the meeting:
    • Demand for Malaysian medical rubber gloves from China has not increased despite the recent spike in Covid cases in the country, mainly due to China’s local supply being more than enough to cater to its domestic demand.
    • PU remained sluggish in Dec 2022 and Jan 2023 at 25%, similar to 1QFY23. This is lower than 40% guided in the most recent analyst briefing. Hence, we believe the losses in the upcoming 2QFY23 results will be similar to 1QFY23.
    • Top Glove maintained its guidance that customers could start replenishing stockpiles in 2QCY23, which is consistent with similar guidance from Hartalega Holdings.
    • According to The Edge, HARPS Holdings acquired Semperit AG Holding’s medical rubber glove manufacturing segment for EUR115mil. Notwithstanding the group’s current low PU and strong net cash position RM359mil as at 30 Nov 2022, management affirmed no intention of engaging in any mergerand-acquisition (M&A) activities to resolve the current oversupply scenario.
    • To recap, the medical rubber glove industry experienced oversupply in the aftermath of the H1N1 pandemic, especially in 2011. Although there were slight M&A consolidation activities back then, the oversupply was resolved by the liquidation of minor players. We note that Top Glove did not acquire smaller players until 2014.
    • By Dec 2025, Top Glove retains its target capacity of 115bil pcs/annum from 100bil pcs/annum currently, while aiming to decommission 2 old and inefficient factories (5% of its current capacity). We view the decommissioning plans positively since this will lower the cost of production and slightly improve the supply-demand dynamics in the industry.
  • The stock currently trades at a FY24F PE of 27x, which is 35% above its 10-year average of 20x. We believe this is unjustified given the unabated challenges of an oversupplied sector globally, which could translate to persistent losses over the next 2 quarters.


Source: AmInvest Research - 16 Jan 2023

Related Stocks
1 person likes this. Showing 0 of 0 comments

Post a Comment